Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study (PROVE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01162356 |
Recruitment Status :
Completed
First Posted : July 14, 2010
Last Update Posted : February 23, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Since the introduction of vitrectomy in 1971, this procedure has become the third most frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed annually in the United States and indications continue to expand. Known long-term complications of vitrectomy are relatively few and include retinal detachment and cataract formation. Although much has been written in the literature concerning acute rises in intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly little information on long term IOP outcomes after vitrectomy. A recent report by Chang given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal of the crystalline lens. A second report by Luk and colleagues reported similar conclusions in a modified cohort. Both studies, were retrospective in nature and did not perform baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted for natural history. Finally, our analysis has not reproduced similar results.
The primary purpose of this study is to analyze the full spectrum of optic nerve and macular changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control for natural history. Baseline evaluations will include examination by fellowship trained retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence tomography (macula and optic nerve) and automated visual field testing. At 3 month then annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.
Condition or disease |
---|
Glaucoma Macular Pucker Macula Hole Vitreomacular Traction Vitreous Opacities or Hemorrhage |
Study Type : | Observational |
Actual Enrollment : | 45 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy |
Actual Study Start Date : | July 2010 |
Actual Primary Completion Date : | January 24, 2017 |
Actual Study Completion Date : | January 24, 2017 |

- Nerve fiber layer and macular changes after vitrectomy [ Time Frame: 3 month and annually for 5 years after surgery ]To determine the incidence of nerve fiber layer (NFL) and macular changes after pars plana vitrectomy, characterize their extent and quality, and determine pre-disposing risk factors.
- Visual field defects [ Time Frame: 3 month and annually for 5 years after surgery ]To characterize long-term functional consequences of NFL or macular changes with regards to peripheral and central visual field defects after PPV.
- Open-angle glaucoma [ Time Frame: 3 month and annually for 5 years after surgery ]To determine the incidence of elevated intraocular pressure and open-angle glaucoma following vitrectomy. Enrolled patients will be screened at baseline to exclude pre-existing glaucoma and post-operative glaucoma screenings will be performed by fellowship trained glaucoma specialist.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Able to consent and comply for the duration of the study and imaging studies
- Media clarity sufficient for imaging studies
- No previous treatment or surgery that might confound study results in the study or fellow eye
- Pars plana vitrectomy (PPV) indicated for epiretinal membrane (ERM), macular hole (MH), vitreo-macular traction (VMT), and vitreous hemorrhage (VH)
Exclusion Criteria:
- Unable to consent and/or comply for the duration of the study and imaging studies
- History of the following conditions: Glaucoma or associated conditions, visual field defects, uveitis, age-related macular degeneration (ARMD), prior PPV for retinal detachment, retained lens or dislocated intraocular lens
- Contralateral eye status post PPV or with advanced eye disease serious enough to warrant future PPV - Contralateral eye with condition that may result in choroidal neovascular membrane

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01162356
United States, Tennessee | |
Vanderbilt Eye Institute | |
Nashville, Tennessee, United States, 37203 |
Principal Investigator: | Stephen J Kim, MD | Vanderbilt Eye Institute | |
Study Director: | Maziar Lalezary, MD | Vanderbilt Eye Institute | |
Study Director: | Rahul K Reddy, MD | Vanderbilt Eye Institute |
Responsible Party: | Stephen J. Kim, MD, Associate Professor of Ophthalmology, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT01162356 |
Other Study ID Numbers: |
100073 |
First Posted: | July 14, 2010 Key Record Dates |
Last Update Posted: | February 23, 2017 |
Last Verified: | February 2017 |
Vitrectomy Glaucoma Macula Optic nerve Ocular Coherence Tomography |
Glaucoma Epiretinal Membrane Hemorrhage Ocular Hypertension |
Eye Diseases Pathologic Processes Retinal Diseases |